Research & Reviews: A Journal of Toxicology

ISSN: 2231-3834

Editors Overview

rrjot maintains an Editorial Board of practicing researchers from around the world, to ensure manuscripts are handled by editors who are experts in the field of study.

Open Access
Special Issue
Topic

Artificial Intelligence in Drug Delivery

Abstract Submission Deadline : November 30, 2023

Manuscript Submission Deadline : December 25, 2023

Special Issue Description

Interventional pharmacology is one of medicine’s strong weapons against diseases. These drugs, be that as they may, can result in harmful side impacts and must be closely observed. Pharmacovigilance is the field of science that screens recognizes, and avoids adverse drug reactions (ADRs). Security efforts start amid the advancement handle, utilizing in vivo and in vitro studies, proceed through clinical trials, and amplify to the postmarketing observation of ADRs in real-world populaces. The utilization of artificial intelligence (AI) has been expanding in different segments of society, especially the pharmaceutical industry. In this survey, we highlight the utilization of AI in different divisions of the pharmaceutical industry, counting medicate disclosure and advancement, drug repurposing, making strides in pharmaceutical efficiency, and clinical trials, among others; such utilization decreases the human workload as well as accomplishing targets in a brief period. With the consideration of AI within the manufacturing of pharmaceutical products, personalized drugs with the specified measurements, discharge parameters, and other required perspectives can be manufactured agreeing to patients’ needs required. Utilizing the most recent AI-based advances will not as it was speeding up the time required for the items to come to the advertising, but will too make strides in the quality of items and the general security of the production process, and give superior utilization of accessible assets alongside being cost-effective, subsequently expanding the significance of automation.

Keywords

Adverse drug reactions (ADRs), Artificial Intelligence (AI), Drugs, Pharmaceutical, Diseases

Manuscript Submission information

Manuscripts should be submitted online via the manuscript Engine. Once you register on APID, click here to go to the submission form. Manuscripts can be submitted until the deadline.
All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the email address:[email protected] for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a Double-blind peer-review process. A guide for authors and other relevant information for the submission of manuscripts is available on the Instructions for Authors page.

Participating journals:

Abbrivation


rrjot

Since

2010

APC

950 $